Psychedelic Medicine Exceptionalism.

Psychedelic medicines are undergoing a research revival, prompting debate over whether they require unique regulatory and ethical treatment or should be held to the same standards as other medical interventions. This article analyzes the arguments for and against special consideration, examining how psychedelics are researched, regulated, commercialized, and administered. It concludes that while psychedelics present distinct features, they do not inherently warrant a separate regulatory framework; instead, existing standards can be adapted to address their specific risks and benefits.

Study at a glance

Abstract

Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical interventions. In other words, identical standards should apply. This article analyzes whether psychedelic medicines warrant special consideration from a regulatory and ethical perspective.